GlassScriptPhysician profile
Stephen R Marshall
NPI 1609847243
$6,218.27
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,132 · 2020: $321 · 2021: $112 · 2022: $1,304 · 2023: $1,689 · 2024: $1,660.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,277 · Education: $72.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,277.04 |
| Education | $72.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,598.11 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $707.11 | 2019-2024 | |
| Janssen Biotech, INC. | $608.47 | 2019-2024 | Tremfya, Simponi, Simponi Aria |
| Amgen INC. | $587.24 | 2019-2024 | Otezla |
| Sun Pharmaceutical Industries INC. | $363.07 | 2019-2024 | Blu-U, Ilumya |
| Lilly USA, LLC | $331.37 | 2019-2024 | Taltz, Olumiant, Zepbound |
| E.R. Squibb & Sons, L.L.C. | $317.44 | 2022-2024 | Sotyktu |
| Genzyme Corporation | $287.80 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $238.38 | 2019-2024 | Dupixent |
| Leo Pharma INC. | $165.36 | 2022-2024 | Adbry |
| Genentech USA, INC. | $144.60 | 2019-2022 | |
| Pfizer INC. | $141.42 | 2019-2024 | |
| Ucb, INC. | $129.04 | 2019-2024 | Bimzelx, Cimzia |
| Celgene Corporation | $88.64 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.23 | 2022-2024 | Spevigo, Cyltezo |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $50.19 | 2022-2023 | Vtama |
| Convatec INC. | $49.72 | 2024 | |
| Incyte Corporation | $39.40 | 2022 | |
| Organon LLC | $39.31 | 2024 | |
| Helsinn Therapeutics (U.S.), INC. | $30.90 | 2020-2022 | |
| Paratek Pharmaceuticals, INC. | $29.41 | 2023 | Nuzyra |
| Vyne Pharmaceuticals INC. | $27.59 | 2020 | |
| Prugen, INC. Pharmaceuticals | $26.01 | 2019 | |
| Smith+Nephew, INC. | $23.63 | 2024 | Oasis |
| Sandoz INC. | $22.87 | 2023 | Hyrimoz |
| Nabriva Therapeutics, Plc | $18.88 | 2022 | |
| Kyowa Kirin, INC. | $18.75 | 2023 | Poteligeo |
| Biocon Biologics INC | $18.67 | 2023 | Hulio |
| Arcutis Biotherapeutics, INC. | $15.60 | 2023 | |
| Kerecis Limited | $13.65 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $11.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Marshall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.